BLOG | Alphawatch

top of page

ORUKA (ORKA): 71% COMPLETE SKIN CLEARANCE AFTER TWO DOSES

ORUKA (ORKA): 71% COMPLETE SKIN CLEARANCE AFTER TWO DOSES

ORUKA (ORKA): 71% COMPLETE SKIN CLEARANCE AFTER TWO DOSES

Biotech & Healthcare

Jonathan Poyer

21 minutes ago3 min read

UiPath's (PATH) Act Two: From Robots to Orchestrating AI

UiPath's (PATH) Act Two: From Robots to Orchestrating AI

UiPath's (PATH) Act Two: From Robots to Orchestrating AI

Robotics & Automation

Jonathan Poyer

2 days ago2 min read

CELLDEX (CLDX) REPORTS POSITIVE PHASE 3 RESULTS FOR BARZOLVOLIMAB IN CSU

CELLDEX (CLDX) REPORTS POSITIVE PHASE 3 RESULTS FOR BARZOLVOLIMAB IN CSU

CELLDEX (CLDX) REPORTS POSITIVE PHASE 3 RESULTS FOR BARZOLVOLIMAB IN CSU

Biotech & Healthcare

Jonathan Poyer

3 days ago2 min read

Red Cat (RCAT) Goes to Sea

Red Cat (RCAT) Goes to Sea

Red Cat (RCAT) Goes to Sea

Robotics & Automation

Jonathan Poyer

Sep 161 min read

Ondas (ONDS) Goes Deeper Into the Weapon System Acquiring Gate Technologies and Bron Technologies

Ondas (ONDS) Goes Deeper Into the Weapon System Acquiring Gate Technologies and Bron Technologies

Ondas (ONDS) Goes Deeper Into the Weapon System Acquiring Gate Technologies and Bron Technologies

Robotics & Automation

Jonathan Poyer

Sep 161 min read

Bonds: Why Duration and Spreads Are Making Bonds Cool Again (Yes, Really)

Bonds: Why Duration and Spreads Are Making Bonds Cool Again (Yes, Really)

Bonds: Why Duration and Spreads Are Making Bonds Cool Again (Yes, Really)

Jonathan Poyer

Sep 161 min read

Why Smart Investors Are Locking Down Yields Before the Market Shifts

Why Smart Investors Are Locking Down Yields Before the Market Shifts

Why Smart Investors Are Locking Down Yields Before the Market Shifts

Jonathan Poyer

Sep 161 min read

DEFINIUM THERAPEUTICS (DFTX): ONE DOSE. THREE POSITIVE PHASE 3 READOUTS.

DEFINIUM THERAPEUTICS (DFTX): ONE DOSE. THREE POSITIVE PHASE 3 READOUTS.

DEFINIUM THERAPEUTICS (DFTX): ONE DOSE. THREE POSITIVE PHASE 3 READOUTS.

Biotech & Healthcare

Jonathan Poyer

Sep 154 min read

Two Big Misses by Novartis (NVS) Has Shareholders Pushing for Board Overhaul

Two Big Misses by Novartis (NVS) Has Shareholders Pushing for Board Overhaul

Two Big Misses by Novartis (NVS) Has Shareholders Pushing for Board Overhaul

Biotech & Healthcare

Jonathan Poyer

Sep 141 min read

AeroVironment (AVAV): $1.5 Billion Backlog — and LOCUST Goes International

AeroVironment (AVAV): $1.5 Billion Backlog — and LOCUST Goes International

AeroVironment (AVAV): $1.5 Billion Backlog — and LOCUST Goes International

Robotics & Automation

Jonathan Poyer

Sep 111 min read

NOVARTIS (NVS): TWO PHASE 3 MISSES IN FOUR DAYS

NOVARTIS (NVS): TWO PHASE 3 MISSES IN FOUR DAYS

NOVARTIS (NVS): TWO PHASE 3 MISSES IN FOUR DAYS

Biotech & Healthcare

Jonathan Poyer

Sep 93 min read

ROIVANT (ROIV): PHASE 2 DATA GETS ATTENTION

ROIVANT (ROIV): PHASE 2 DATA GETS ATTENTION

ROIVANT (ROIV): PHASE 2 DATA GETS ATTENTION

Biotech & Healthcare

Jonathan Poyer

Sep 91 min read

SoundHound (SOUN) Gets Bigger — and Moves Beyond Voice

SoundHound (SOUN) Gets Bigger — and Moves Beyond Voice

SoundHound (SOUN) Gets Bigger — and Moves Beyond Voice

Robotics & Automation

Jonathan Poyer

Sep 91 min read

Palladyne AI (PDYN) + FANUC: Giving Industrial Robots a Smarter Brain

Palladyne AI (PDYN) + FANUC: Giving Industrial Robots a Smarter Brain

Palladyne AI (PDYN) + FANUC: Giving Industrial Robots a Smarter Brain

Robotics & Automation

Jonathan Poyer

Sep 91 min read

UiPath (PATH): AI Agents Are Growing Up — and So Are the Financials

UiPath (PATH): AI Agents Are Growing Up — and So Are the Financials

UiPath (PATH): AI Agents Are Growing Up — and So Are the Financials

Robotics & Automation

Jonathan Poyer

Sep 42 min read

AeroVironment (AVAV) Lands $464.8M Army Contract — Lasers Move Into Production

AeroVironment (AVAV) Lands $464.8M Army Contract — Lasers Move Into Production

AeroVironment (AVAV) Lands $464.8M Army Contract — Lasers Move Into Production

Robotics & Automation

Jonathan Poyer

Sep 41 min read

GLP-1s are All the Rage - Let's Dig Into That

GLP-1s are All the Rage - Let's Dig Into That

GLP-1s are All the Rage - Let's Dig Into That

Biotech & Healthcare

Jonathan Poyer

Sep 32 min read

Lilly (LLY) Paying $2.9B for a Phase 1 Biotech Merida Biosciences

Lilly (LLY) Paying $2.9B for a Phase 1 Biotech Merida Biosciences

Lilly (LLY) Paying $2.9B for a Phase 1 Biotech Merida Biosciences

Biotech & Healthcare

Jonathan Poyer

Sep 32 min read

When the Shock Absorber Stops Absorbing

When the Shock Absorber Stops Absorbing

When the Shock Absorber Stops Absorbing

Jonathan Poyer

Sep 24 min read

What are the Medical & Investment Implication of Psychedelics

What are the Medical & Investment Implication of Psychedelics

What are the Medical & Investment Implication of Psychedelics

Biotech & Healthcare

Jonathan Poyer

Sep 21 min read

bottom of page